Engineers Gate Manager’s CytomX Therapeutics CTMX Stock Holding History

Engineers Gate Manager’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$312K	Buy	83,130 +53,653	+182%	+$205K	﹤0.01%	1762
2026 Q1	$139K	Buy	29,477 +2,938	+11%	+$14.9K	﹤0.01%	1982
2025 Q4	$113K	Buy	+26,539	New	+$101K	﹤0.01%	1903
2023 Q1	–	Sell	-10,135	Closed	-$16.2K	–	1710
2022 Q4	$16.2K	Sell	10,135 -551	-5%	-$815	﹤0.01%	1611
2022 Q3	$15K	Sell	10,686 -16,928	-61%	-$26.1K	﹤0.01%	1543
2022 Q2	$51K	Buy	27,614 +90	+0.3%	+$172	﹤0.01%	1788
2022 Q1	$73K	Sell	27,524 -41,429	-60%	-$159K	﹤0.01%	1738
2021 Q4	$299K	Buy	+68,953	New	+$404K	0.01%	1411
2021 Q3	–	Sell	-55,035	Closed	-$348K	–	1698
2021 Q2	$348K	Buy	55,035 +25,535	+87%	+$199K	0.02%	1033
2021 Q1	$228K	Buy	+29,500	New	+$233K	0.01%	1515
2020 Q4	–	Sell	-28,409	Closed	-$189K	–	1742
2020 Q3	$189K	Sell	28,409 -17,577	-38%	-$130K	0.01%	1442
2020 Q2	$383K	Buy	45,986 +32,786	+248%	+$304K	0.02%	1088
2020 Q1	$101K	Buy	+13,200	New	+$92K	0.01%	1413

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Engineers Gate Manager's CTMX Position: Q2 2026 in Review

Engineers Gate Manager increased its CytomX Therapeutics (CTMX) stake by 182% in Q2 2026, buying an estimated $205K and bringing the position to 83,130 shares worth $312K. The position accounts for ﹤0.01% of the portfolio, ranked #1762.

Engineers Gate Manager first reported a position in CTMX in Q1 2020 and has held it in 13 quarters since. The position peaked at $383K in Q2 2020. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Engineers Gate Manager held 83,130 shares of CytomX Therapeutics worth $312K as of Q2 2026.
Engineers Gate Manager bought 53,653 CytomX Therapeutics shares in Q2 2026, an estimated $205K.
CytomX Therapeutics made up ﹤0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #1762 holding.
Engineers Gate Manager first reported a position in CytomX Therapeutics in Q1 2020 and has held it in 13 quarters since.
Engineers Gate Manager's CytomX Therapeutics position peaked at $383K in Q2 2020.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.